Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor Inhibitor treatment in lethal prostate cancer

Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous and the molecular underpinnings of ARSi resistance are not well elucidated. Here we performed transcriptome analysis of circulating tumor cells (CTCs) and peripheral blood mononuclear cells (PBMC) in the context of a prospective clinical trial of men with mCRPC treated with abiraterone (Abi) or enzalutamide (Enza). Our goal is to uncover potential molecular mechanisms underlying intrinsic (de novo) or acquired resistance to ARSi treatment for patients with mCRPC.